Amedisys (AMED) Tops Q2 EPS by 24c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts AMED Hot Sheet
Price: $100.99 --0%
Financial Fact:
Operating income: 14.36M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Financial Fact:
Operating income: 14.36M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Amedisys (NASDAQ: AMED) reported Q2 EPS of $1.47, $0.24 better than the analyst estimate of $1.23. Revenue for the quarter came in at $557.9 million versus the consensus estimate of $583.12 million.
GUIDANCE:
Amedisys sees FY2022 revenue of $2.29-2.31 billion, versus the consensus of $2.35 billion.
For earnings history and earnings-related data on Amedisys (AMED) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- RBC Capital Reiterates Outperform Rating on Verisk Analytics (VRSK)
- Truist names top clean energy stocks to watch ahead of Q3 earnings season
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
